The MEK inhibitors trametinib and cobimetinib were approved for the treatment of metastatic melanoma in 2013 and 2015, respectively, and target MAPK signalling which is upregulated in several forms of cancer. The gene discussed is MAP2K7; the disease is metastatic melanoma.